China’s NMPA has published revised Good Clinical Practice regulations that enter into force in September, updating clinical trial governance requirements with specific emphasis on data governance and compliance with international ethical principles. The update is the first since 2020 and adds explicit expectations for transparent recording, processing, and storage of clinical trial materials, including participant privacy controls. The revisions also reaffirm patient rights and safety as primary considerations, referencing Declaration of Helsinki principles. Sponsors, CROs, and research sites are expected to update data management and compliance workflows ahead of the effective date.